SCHEMBL11297579

SCHEMBL11297579

NS(=O)(=O)c1ccc(Nc2ncc3c(n2)-c2ccccc2CCC3)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 14/20 1.00
CA1 P00915 5/20 0.66
CA2 P00918 5/20 0.66
CA9 Q16790 5/20 0.66
CA12 O43570 4/20 0.66
CA4 P22748 1/20 0.58
CCNT1 O60563 1/20 0.52
CDK1 P06493 1/20 0.52
CCNB1 P14635 1/20 0.52
CCNA2 P20248 1/20 0.52
CCNE1 P24864 1/20 0.52
CDK2 P24941 1/20 0.52
CCND3 P30281 1/20 0.52
FLT3 P36888 1/20 0.52
CDK9 P50750 1/20 0.52
CDK6 Q00534 1/20 0.52
CDK5 Q00535 1/20 0.52
CDK5R1 Q15078 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3520848 0.95 IKBKB (1.00) IKBKBCA1CA2CA9CA12
SCHEMBL11297594 0.88 IKBKB (0.78) IKBKBCA1CA2CA9CA12
SCHEMBL11296744 0.85 IKBKB (0.73) IKBKBCCNT1CDK1CCNB1CCNA2
SCHEMBL11299366 0.83 IKBKB (0.71) IKBKBCCNT1CDK1CCNB1CCNA2
SCHEMBL13439677 0.83 IKBKB (0.71) IKBKBCA1CA2CA9CA12
SCHEMBL11299433 0.83 IKBKB (0.71) IKBKBCCNA2CDK2CDK5CDK5R1
SCHEMBL11296762 0.83 IKBKB (0.71) IKBKBCCNA2CDK2CDK5CDK5R1
SCHEMBL11296777 0.83 IKBKB (0.71) IKBKBCA1CA2CA9CA12
SCHEMBL11312691 0.82 IKBKB (0.70) IKBKBCA1CA2CA9CA12
SCHEMBL2434868 0.80 CDK2 (0.74) IKBKBCCNT1CDK1CCNB1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288400-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-16 US disclosed
US-20120183577-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-19 US disclosed
US-8017619-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-13 US disclosed
US-20100280026-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-11-04 US disclosed
US-7700609-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-20 US disclosed
EP-1692140-B1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280026-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K6 IKBKB 540/4885CA1 4066/4885CA2 2721/4885
US-20120183577-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K6 IKBKB 540/4885CA1 4066/4885CA2 2721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.